secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2023-10-10T23:59:59+00:00
Accession:  0001193125-23-252523
Event type: other_material
Sentiment:  negative
Materiality: 0.95
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea appoints Cameron Turtle as PEO; discloses substantial doubt about going concern
--------------------------------------------------------------------------------

- Cameron Turtle appointed principal executive officer effective Oct 6, 2023; previously COO since June 2023.
- Company received SEC waiver to file abbreviated financials for Spyre acquisition; net liabilities assumed of $17.0M.
- Substantial doubt about going concern if stockholders do not timely approve Series A Preferred Stock conversion.
- As of June 22, 2023, Spyre had cash $3.0M and accrued liabilities $20.0M; total acquisition cost was $113.2M.
- Company reduced workforce by 83% in April 2023 to ~10 employees; exploring strategic alternatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523252523/0001193125-23-252523-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523252523/d493616d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-252523

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer